An evolution from pilot to a commercial contract should be a given, based on the efficacy of the product and the relationships at director level between the two companies. A 23.5% increase post-announcement suggests this was surprisingly not baked into the SP.
I place far more weight on the revenue figure in the next 4C that represents the value of the technology to Integral and others in real commercial terms. 4Dmedical has a contract with Imed that is a bigger player than Integral. This should be generating $$$. A contract is not revenue.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.005(2.04%) |
Mkt cap ! $116.3M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 26.0¢ | 24.5¢ | $300.4K | 1.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 122326 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.20pm 24/06/2025 (20 minute delay) ? |
| 4DX (ASX) Chart |